A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder
Latest Information Update: 11 Oct 2021
At a glance
- Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Alkermes plc
- 10 Mar 2020 Results published in the Journal of Clinical Psychiatry
- 23 May 2018 According to the Alkermes media release, data from this study will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
- 09 May 2018 Primary endpoint (Time to first event of exacerbation of disease: ALKS3831 versus OLZ+PBO) has not been met, according to primary outcome details presented at the 171st Annual Meeting of the American Psychiatric Association.